Has Sarah Weatherspoon received payments from drug or device companies?

Yes. Drug and device makers reported $103,131 in general payments to Sarah Weatherspoon across 245 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sarah Weatherspoon did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sarah Weatherspoon come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sarah Weatherspoon

Epilepsy · Memphis, TNNPI 1407021389

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $67,560 of the $103,131 with a category attached, or 65.5%. Neurelis, Inc. accounts for 76.0% of it on its own, with 20 other manufacturers making up the rest.

$103,131in general payments, 2019–2025

Across 245 payments — averaging $420.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurelis, Inc.$78K
UCB, Inc.$20K
Mallinckrodt Enterprises LLC$2K
Neuropace, Inc.$733
Upsher-smith Laboratories LLC$563
Acadia Pharmaceuticals Inc$476
plus $1K from 15 others

$67,531in research payments, 2019–2025

Across 42 payments — averaging $1607.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Immedica Pharma US, Inc.$58K
Jazz Pharmaceuticals Inc.$10K

What the payments were for

Consulting fees$11,69011%
Speaking & faculty fees$67,56066%
Travel & lodging$17,74817%
Food & beverage$6,1206%
Education$130%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurelis, Inc.	122	$78,331
UCB, Inc.	51	$19,982
Mallinckrodt Enterprises LLC	3	$1,800
Neuropace, Inc.	5	$733
Upsher-smith Laboratories LLC	21	$563
Acadia Pharmaceuticals Inc	5	$476
Jazz Pharmaceuticals Inc.	6	$289
Livanova USA, Inc.	4	$205
SK Life Science, Inc.	7	$155
PTC Therapeutics, Inc.	1	$125
Greenwich Biosciences, Inc.	1	$83
ITF Therapeutics LLC	2	$68
Catalyst Pharmaceuticals, Inc.	3	$66
Immedica Pharma US, Inc.	2	$45
Azurity Pharmaceuticals, Inc.	2	$41
Biocodex, Inc.	2	$39
Otter Pharmaceuticals, LLC	2	$37
Supernus Pharmaceuticals, Inc.	2	$35
Eisai Inc.	2	$30
Travere Therapeutics, Inc.	1	$15
Zogenix Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few epilepsy providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EpidiolexCannabidiol (Cbd)	12	$112,063
Everolimus	12	$99,223
XcopriCenobamate	12	$13,609
Lacosamide	21	$2,830
Clonazepam	31	$497
Levetiracetam	13	$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
SK Life Science, Inc.Xcopri	$155	$13,60912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in Tennesseeon file to place this against a meaningful peer group, so we don't.

Other epilepsy in Memphis

Basanagoud MudigoudarMemphis$2K
Amy PattersonMemphis$2K
Amy McGregorMemphis$2K
Nitish ChourasiaMemphis$1K
Hae Won ShinMemphis$850
Samir BangaloreNashville$134K
Martin GallagherNashville$4K
Angela CrudeleNashville$2K
Zachary MillsChattanooga$1K
William NobisNashville$1K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →